Takeda has put forward a new proposed bid for Shire, increasing the cash portion of the deal.
News
CHMP rejects AB Science’s ALS drug
AB Science’s share price has taken a hit after European Medicine Agency’s advisors rejected approval of masitinib for amyotrophic lateral sclerosis.
Communications Team of the Year: Join our exclusive alumni of fellow Pharma winners!
The PharmaTimes Communications Team of the Year competition is the only pharma industry award that tests the competencies and potential of communications agency teams, benchmarking talent agency side – and as such, entry is a must.
Clinical Researcher of the Year finalists to face toughest challenge yet
With just 9 days to go until the prestigious PharmaTimes Clinical Researcher of the Year Awards Ceremony, the 2018 finalists are gearing up for their biggest challenge yet.
Shire turns down Takeda’s advances
Shire has now confirmed that it has thus far rejected three merger proposals from Takeda, the last one being valued at around $44 billion.
FDA advisors back approval of GW’s Epidiolex
As expected, an FDA advisory panel has backed approval of GW Pharmaceuticals/Greenwich Bioscience’s Epidiolex for treating seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.
US widens use of AZ’ Tagrisso in lung cancer
AstraZeneca’s Tagrisso has been approved in the US as a first-line treatment for patients with metastatic non-small-cell lung cancer whose tumours have epidermal growth factor receptor (EGFR) mutations.
Merck sells consumer healthcare unit to P&G
Germany’s Merck is selling its consumer health unit to Procter & Gamble for around for 3.4 billion Euros.
A great mix of companies represented at International Clinical Researcher of the Year
Having seen some outstanding performances from individuals and teams at the PharmaTimes International Clinical Researcher of the Year finals days, the 2018 PharmaTimes International Clinical Researcher of the Year Awards Ceremony looks set to be one of the best yet.
FDA clears first therapy for inherited rickets
US regulators have approved the first drug to treat adults and children with x-linked hypophosphatemia (XLH), a rare, inherited form of rickets.
Final NHS nod for Roche’s RoActemra
Roche/Chugai’s RoActemra should be routinely offered throughout the NHS to adults with giant cell arteritis (GCA) within the next three months, following a final green light from cost regulators.
GW’s Epidiolex takes a leap toward US approval
Shares in GW Pharma were given a boost after its cannabinoid Epidiolex took a giant leap towards US approval for treating seizures linked with Lennox-Gastaut (LGS) and Dravet syndromes.
MPs slate rate of progress on NHS cyber security
MPs have criticised the government’s slow response to last year’s WannaCry attack on the NHS, and warn there is much work to be done to improve cyber security if damage from the next attack is to be minimised.
GSK picks Kevin Sim to lead business development for pharma R&D
GlaxoSmithKline has named Kevin Sim as senior vice president and head of worldwide business development for pharmaceuticals R&D.
CR UK, AACR form international cancer alliance
Cancer Research UK and the American Association for Cancer Research (AACR) are launching a new international alliance dedicated to accelerating progress against cancer.
